Xuxi Zhang

Supplementary Table S5 GRADE Evidence Profile: New onset DR Quality assessment No of patients Effect Quality Importance No of studies Design Risk of bias Inconsistency Indirectness Imprecision Other considerations Interventions targeting modifiable risk factors of DR Control Relative (95% CI) Absolute New Onset DR (follow ‐ up 1 to 7.5 years) 11 randomised trials serious 1 no serious inconsistency no serious indirectness no serious imprecision strong association 2 220/3013 (7.3%) 260/2868 (9.1%) OR 0.60 (0.45 to 0.79) 34 fewer per 1000 (from 18 fewer to 48 fewer)  HIGH CRITICAL New Onset DR: Blood ‐ pressure ‐ control intervention (follow ‐ up 5 to 7.5 years) 2 randomised trials no serious risk of bias no serious inconsistency no serious indirectness serious 3 none 101/269 (37.5%) 82/177 (46.3%) OR 0.68 (0.41 to 1.14) 93 fewer per 1000 (from 202 fewer to 33 more)  MODERATE IMPORTANT New Onset DR: Glycemic ‐ control intervention (follow ‐ up 1 ‐ 6 years) 4 randomised trials very serious 4 no serious inconsistency no serious indirectness no serious imprecision none 62/186 (33.3%) 77/194 (39.7%) OR 0.70 (0.31 to 1.57) 82 fewer per 1000 (from 227 fewer to 111 more)  LOW IMPORTANT New Onset DR: Dietry ‐ control intervention (follow ‐ up 6 years) 2 randomised trials no serious risk of bias no serious inconsistency no serious indirectness serious 3 none 42/2424 (1.7%) 64/2380 (2.7%) OR 0.64 (0.43 to 0.95) 10 fewer per 1000 (from 1 fewer to 15 fewer)  MODERATE IMPORTANT New Onset DR: Multifactorial intervention (follow ‐ up 1.9 to 4.3 years) 3 randomised trials serious 5 no serious inconsistency no serious indirectness no serious imprecision none 15/134 (11.2%) 37/117 (31.6%) OR 0.27 (0.14 to 0.53) 205 fewer per 1000 (from 119  MODERATE IMPORTANT 7 195 Prevention and control of diabetic retinopathy